Literature DB >> 8269596

Bryostatin 1 induces productive Epstein-Barr virus replication in latently infected cells: implications for use in immunocompromised patients.

J P Stewart1, A T McGown, J Prendiville, G R Pettit, B W Fox, J R Arrand.   

Abstract

Bryostatin 1 is a novel anti-tumor agent currently undergoing clinical trial. We investigated the effect of this drug on B-lymphocyte cell lines that carry the Epstein-Barr virus and found that it induces these latently infected cells into the production of transforming virus particles over a wide range of concentrations. These results may have clinical implications, particularly with regard to the use of the drug in the immunocompromised patient.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8269596     DOI： 10.1007/bf00686030

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  11 in total

1.  Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity.

Authors:  R L Hornung; J W Pearson; M Beckwith; D L Longo
Journal:  Cancer Res       Date:  1992-01-01       Impact factor: 12.701

2.  Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line.

Authors:  C D Gregory; M Rowe; A B Rickinson
Journal:  J Gen Virol       Date:  1990-07       Impact factor: 3.891

3.  Persisting oncogenic herpesvirus induced by the tumour promotor TPA.

Authors:  H zur Hausen; F J O'Neill; U K Freese; E Hecker
Journal:  Nature       Date:  1978-03-23       Impact factor: 49.962

4.  Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes.

Authors:  G Miller; T Shope; H Lisco; D Stitt; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1972-02       Impact factor: 11.205

5.  Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen.

Authors:  G J Hoffman; S G Lazarowitz; S D Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

6.  Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin.

Authors:  H Hennings; P M Blumberg; G R Pettit; C L Herald; R Shores; S H Yuspa
Journal:  Carcinogenesis       Date:  1987-09       Impact factor: 4.944

7.  The Epstein-Barr virus candidate vaccine antigen gp340/220 is highly conserved between virus types A and B.

Authors:  J F Lees; J E Arrand; S D Pepper; J P Stewart; M Mackett; J R Arrand
Journal:  Virology       Date:  1993-08       Impact factor: 3.616

8.  Bryostatins: potent, new mitogens that mimic phorbol ester tumor promoters.

Authors:  J B Smith; L Smith; G R Pettit
Journal:  Biochem Biophys Res Commun       Date:  1985-11-15       Impact factor: 3.575

9.  Successful treatment of murine melanoma with bryostatin 1.

Authors:  L M Schuchter; A H Esa; S May; M K Laulis; G R Pettit; A D Hess
Journal:  Cancer Res       Date:  1991-01-15       Impact factor: 12.701

10.  Bryostatin 1, an activator of protein kinase C, mimics as well as inhibits biological effects of the phorbol ester TPA in vivo and in vitro.

Authors:  M Gschwendt; G Fürstenberger; S Rose-John; M Rogers; W Kittstein; G R Pettit; C L Herald; F Marks
Journal:  Carcinogenesis       Date:  1988-04       Impact factor: 4.944
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.